Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$4.19 - $7.95 $241,997 - $459,160
-57,756 Reduced 38.14%
93,672 $562,000
Q2 2022

Aug 08, 2022

SELL
$2.59 - $4.3 $285,897 - $474,655
-110,385 Reduced 42.16%
151,428 $627,000
Q1 2022

May 16, 2022

BUY
$3.78 - $5.32 $989,653 - $1.39 Million
261,813 New
261,813 $995,000

About Satsuma Pharmaceuticals, Inc.


  • Ticker STSA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,587,500
  • Description
  • Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...
More about STSA
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.